Safety and efficacy of first-line Osimertinib therapy including the frequency of drug-induced lung disease
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000044863
- Lead Sponsor
- Kobe University Graduates School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 133
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients who have requested not to participate in this study based on the published information. 2.Patients who are currently participating or will participate in clinical research involving interventions related to pharmacotherapy. 3.Other patients who are judged ineligible by the principal investigator.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the frequency of drug-induced lung disease
- Secondary Outcome Measures
Name Time Method